Summary
Elite Pharmaceuticals, Inc. (Elite), incorporated on October 1, 1997, is a specialty pharmaceutical company. The Company is principally engaged in the development and manufacture of oral, controlled-release products. The Company owns, licenses or contract manufactures various products, including phentermine hydrochloric acid (HCl) 37.5 milligram tablets for bariatric, methadone HCl 10 milligram tablets and hydromorphone HCl 8 milligram tablets for pain, phendimetrazine tartrate 35 milligram tablets for bariatric, phentermine HCl 15 milligram and 30 milligram capsules for bariatric, naltrexone HCl50 milligram tablets for pain, isradipine 2.5 milligram and 5 milligram capsules for cardiovascular diseases,and hydroxyzine HCl 10 milligram, 25 milligram and 50 milligram tablets, which are antihistamines. The Company also owns ELI200, an undisclosed opioid with sequestered naltrexone capsules. The Company's Northvale Facility operates under current good manufacturing practice (cGMP) and is a United States Drug Enforcement Agency (DEA) registered facility for research, development and manufacturing. Elite performs manufacturing and packaging of methadone 10 milligrams, and manufacturing of hydromorphone 8 milligrams and phendimetrazine 35 milligrams, among its other products.
No comments:
Post a Comment